Ichnos Glenmark Innovation Inc (IGI), a clinical-stage biotechnology company focused on developing Multispecific therapeutics in oncology, announced on Tuesday the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for ISB 2301.
According to the company, ISB 2301 is a first-in-class, investigational multispecific immune cell activator designed to target three tumour-associated antigens and engage both T cells and NK cells. This pentaspecific molecule combines five binding specificities: three tumour-associated antigens, plus T-cell and NK-cell activation. By combining tumour-cell recognition with complementary immune activity, ISB 2301 is being developed to address biological heterogeneity and immune-suppressive features of solid tumours.
ISB 2301 was engineered using IGI's proprietary BEAT Multispecific Platform and is designed to recognise three tumour-associated antigens while engaging both T cells and NK cells through complementary mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), checkpoint inhibition, and the induction of a sustained type 1 immune response.
In preclinical studies, ISB 2301 demonstrated favourable pharmacokinetic and tolerability profiles in non-human primates, supporting the planned evaluation of its safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumour activity in patients with advanced solid tumours.
ViiV Healthcare receives positive EU recommendation for expanded paediatric HIV treatments
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Sunnyside adds GLP-1 options to its medication program for Alcohol Use Disorder
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme
Shanton Pharma's SAP-001 receives EMA and FDA paediatric study waivers in hyperuricaemia
Ascletis announces submission of US IND application for oral obesity combination therapy
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
bioMérieux secures FDA clearance for updated gastrointestinal diagnostic panels
Photocure maintains 2028 Medicare coverage target for AssureMDx following CMS update